Fig. 3
From: Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
a Specificity of uptake of 111In-bevacizumab. Uptake of 111In-bevacizumab (black); 111In-bevacizumab + excess of unlabelled bevacizumab (hatched) and 111In-IgG1κ (white) in different tumour models. Data are presented as mean ± SEM, *P < 0.05; ****P < 0.0001, n = minimum of 4 mice/group. b SPECT-CT transaxial image of FaDu xenograft-bearing mice injected with either 111In-bevacizumab or 111In-IgG1κ (tumours in circles)